top of page

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™

Updated: May 21, 2022

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment

CHICAGO (BUSINESS WIRE) – TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory Tcell (Treg) therapy, announced today that it has launched the TRACT CryoBanking Program to enable individuals to donate their blood consisting of their immune cells for future treatments as they become commercially available. The banked cells could be utilized to treat a number of conditions or diseases that are currently being investigated with novel cell therapy treatments such as indications in organ transplantation or autoimmune diseases.

The CryoBanking Program, offered by TRACT Therapeutics is a leadingedge program developed specifically for patients who choose to bank their immune cells today for future use. Gretchen S Johnson, President and CEO of TRACT Therapeutics, commented on the importance of the program:

“The banking of immune cells for future therapeutic use has unprecedented potential for the patient, opening up new treatment possibilities that may someday provide medical options for some of the most serious diseases.”

Dan Dickinson, Chairman, Northwestern Medicine Transplant Advisory Council and organ transplant recipient stated, “TRACT Therapeutics has pioneered an innovative program at Northwestern Medicine that offers any individual who chooses to bank their immune cells, an extra layer of protection in planning for their future medical needs.”


About TRACT Therapeutics

TRACT Therapeutics, Inc. is a clinical stage biotechnology company developing a novel therapeutic approach to restoring immune balance in organ transplantation and autoimmune disease. Its proprietary platform technology, using autologous polyclonally expanded regulatory Tcells was developed at Northwestern University by pioneer, Joseph R Leventhal, MD, PhD and his research colleagues. TRACT has recently received FDA approval to initiate a Phase 2 trial with Trigs in kidney recipients.

This press release contains forwardlooking statements that express the belief, potential anticipation or expectation, as well as other statements which are not historical fact, and statements related to clinical trials and their results, design, FDA product approvals or other marketing approvals, features, functionality and performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward looking statements.

Recent Posts

See All


bottom of page